{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:30:51Z","timestamp":1755217851485,"version":"3.43.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.josat.2025.209744","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T19:30:29Z","timestamp":1750879829000},"page":"209744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Evaluation of a primary care-based Medication for Opioid Use Disorder (MOUD) program in a fully-integrated federally qualified health center"],"prefix":"10.1016","volume":"176","author":[{"given":"Karen","family":"Howard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Stover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Suchocki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"American Society of Addiction Medicine","key":"10.1016\/j.josat.2025.209744_bb0005"},{"key":"10.1016\/j.josat.2025.209744_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108548","article-title":"Associations of retention on buprenorphine for opioid use disorder with patient characteristics and models of care in the primary care setting","volume":"131","author":"Bailey","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"RR-11","key":"10.1016\/j.josat.2025.209744_bb0015","first-page":"1","article-title":"Framework for program evaluation in public health","volume":"48","author":"Centers for Disease Control and Prevention","year":"1999","journal-title":"MMWR"},{"author":"Centers for Disease Control and Prevention","key":"10.1016\/j.josat.2025.209744_bb0020"},{"author":"Centers for Disease Control and Prevention","key":"10.1016\/j.josat.2025.209744_bb0025"},{"issue":"8","key":"10.1016\/j.josat.2025.209744_bb0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.25999","article-title":"Buprenorphine prescribing characteristics following relaxation of X-Waiver training requirements","volume":"7","author":"Christine","year":"2024","journal-title":"JAMA Network Open"},{"author":"Clackamas County","key":"10.1016\/j.josat.2025.209744_bb0035"},{"author":"Clackamas County","key":"10.1016\/j.josat.2025.209744_bb0040"},{"author":"Clackamas County","key":"10.1016\/j.josat.2025.209744_bb0045"},{"author":"Clackamas County Parole and Probation","key":"10.1016\/j.josat.2025.209744_bb0050"},{"key":"10.1016\/j.josat.2025.209744_bb0055","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/s11606-019-04943-6","article-title":"The role of primary care in improving access to medication-assisted treatment for rural Medicaid enrollees with opioid use disorder","volume":"34","author":"Cole","year":"2019","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.josat.2025.209744_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2020.557275","article-title":"Patient satisfaction with medications for opioid use disorder treatment via telemedicine: Brief literature review and development of a new assessment","volume":"8","author":"Cole","year":"2021","journal-title":"Frontiers in Public Health"},{"issue":"5","key":"10.1016\/j.josat.2025.209744_bb0065","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11920-020-01149-0","article-title":"Identification and management of opioid use disorder in primary care: An update","volume":"22","author":"Donroe","year":"2020","journal-title":"Current Psychiatry Reports"},{"key":"10.1016\/j.josat.2025.209744_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108350","article-title":"The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017","volume":"218","author":"Florence","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"author":"Harvard School of Public Health","key":"10.1016\/j.josat.2025.209744_bb0075"},{"author":"Health Resources and Services Administration","key":"10.1016\/j.josat.2025.209744_bb0080"},{"issue":"2","key":"10.1016\/j.josat.2025.209744_bb0085","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1080\/02791072.2011.587704","article-title":"Integrating buprenorphine treatment into a public healthcare system: The San Francisco Department of Public Health\u2019s office-based buprenorphine pilot program","volume":"43","author":"Hersh","year":"2011","journal-title":"Journal of Psychoactive Drugs"},{"issue":"78","key":"10.1016\/j.josat.2025.209744_bb0090","article-title":"Prescribers\u2019 satisfaction with delivering medication for opioid use disorder","volume":"16","author":"Knudsen","year":"2021","journal-title":"Substance Abuse Treatment, Prevention, and Policy"},{"key":"10.1016\/j.josat.2025.209744_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019","volume":"110","author":"Krawczyk","year":"2022","journal-title":"The International Journal of Drug Policy"},{"issue":"116712","key":"10.1016\/j.josat.2025.209744_bb0100","article-title":"Long-term treatment retention in West Viriginia\u2019s comprehensive opioid addiction treatment (COAT) program","volume":"411","author":"Lander","year":"2020","journal-title":"Journal of the Neurological Sciences"},{"issue":"10118","key":"10.1016\/j.josat.2025.209744_bb0105","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.josat.2025.209744_bb0110","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.54772","article-title":"Medication for opioid use disorder in Federally Qualified Health Centers","volume":"8","author":"Lindenfeld","year":"2025","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1016\/j.josat.2025.209744_bb0115","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/SAR.S38902","article-title":"The Treatment Effectiveness Assessment (TEA): An efficient, patient-centered instrument for evaluating progress in recovery from addiction","volume":"3","author":"Ling","year":"2012","journal-title":"Substance Abuse and Rehabilitation"},{"key":"10.1016\/j.josat.2025.209744_bb0120","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/SAR.S198361","article-title":"Measuring recovery in opioid use disorder: Clinical utility and psychometric properties of the Treatment Effectiveness Assessment","volume":"10","author":"Ling","year":"2019","journal-title":"Substance Abuse and Rehabilitation"},{"issue":"1","key":"10.1016\/j.josat.2025.209744_bb0125","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/ADM.0b013e318233d621","article-title":"Comparison of buprenorphine treatment for opioid dependence in three settings","volume":"6","author":"Miotto","year":"2012","journal-title":"Journal of Addiction Medicine"},{"issue":"3","key":"10.1016\/j.josat.2025.209744_bb0130","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.sapharm.2023.12.001","article-title":"Is there a disparity in medications for opioid use disorder based on race\/ethnicity and gender? A systematic review and meta-analysis","volume":"20","author":"Nedjat","year":"2024","journal-title":"Research in Social and Administrative Pharmacy"},{"issue":"5","key":"10.1016\/j.josat.2025.209744_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232086","article-title":"Retention of patients in opioid substitution treatment: A systematic review","volume":"15","author":"O\u2019Connor","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.josat.2025.209744_bb0140","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1377\/hlthaff.2019.01622","article-title":"Buprenorphine treatment by primary care providers, psychiatrists, addiction specialists, and others","volume":"39","author":"Olfson","year":"2020","journal-title":"Health Affairs"},{"author":"Oregon Health Authority","key":"10.1016\/j.josat.2025.209744_bb0145"},{"issue":"1","key":"10.1016\/j.josat.2025.209744_bb0150","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/JAN.0000000000000516","article-title":"Buprenorphine program evaluation in a private psychiatric office-based practice","volume":"34","author":"Palmer","year":"2023","journal-title":"Journal of Addictions Nursing"},{"year":"2024","series-title":"Opportunities to promote Medications for opioid use disorder in Federally Qualified Health Centers","author":"Schulman","key":"10.1016\/j.josat.2025.209744_bb0155"},{"issue":"2","key":"10.1016\/j.josat.2025.209744_bb0160","doi-asserted-by":"crossref","first-page":"89","DOI":"10.21106\/ijma.284","article-title":"Opioid epidemic in the United States: Empirical trends, and a literature review of social determinants and epidemiological, pain management, and treatment patterns","volume":"8","author":"Singh","year":"2019","journal-title":"International Journal of Maternal and Child Health and AIDS"},{"key":"10.1016\/j.josat.2025.209744_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108176","article-title":"Signal of increased opioid overdose during COVID-19 from emergency medical services data","volume":"214","author":"Slavova","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"author":"State of Oregon Employment Department","key":"10.1016\/j.josat.2025.209744_bb0170"},{"key":"10.1016\/j.josat.2025.209744_bb0175","unstructured":"Substance Abuse and Mental Health Services Administration. (n.d.). Buprenorphine practitioner locator. https:\/\/www.samhsa.gov\/medication-assisted-treatment\/find-treatment\/treatment-practitioner-locator?field_bup_lat_lon_proximity%5Bvalue%5D=25&field_bup_lat_lon_proximity%5Bsource_configuration%5D%5Borigin_address%5D=97045&field_bup_city_value=&field_bup_state_value=43&page=9."},{"issue":"1","key":"10.1016\/j.josat.2025.209744_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227968","article-title":"Interventions for incarcerated adults with opioid use disorder in the United States: A systematic review with a focus on social determinants of health","volume":"15","author":"Sugarman","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.josat.2025.209744_bb0185","unstructured":"U.S. Census Bureau. (n.d.). Explore census data. https:\/\/www.data.census.gov."},{"author":"U.S. Food and Drug Administration","key":"10.1016\/j.josat.2025.209744_bb0190"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875925001237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875925001237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T20:25:46Z","timestamp":1754425546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875925001237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":38,"alternative-id":["S2949875925001237"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2025.209744","relation":{},"ISSN":["2949-8759"],"issn-type":[{"type":"print","value":"2949-8759"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of a primary care-based Medication for Opioid Use Disorder (MOUD) program in a fully-integrated federally qualified health center","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2025.209744","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"209744"}}